NYSSEN, Olga, Pietro PRATESI, Miguel SPINOLA, Laimas JONAITIS, Angeles PEREZ-AISA, Dino VAIRA, Ilaria Maria SARACINO, Matteo PAVONI, Giulia FIORINI, Bojan TEPES, Dmitry BORDIN, Irina VOYNOVAN, Angel LANAS, Samuel MARTINEZ-DOMINGUEZ, Enrique ALFARO, Luis BUJANDA, Manuel PABON-CARRASCO, Luis HERNANDEZ, Antonio GASBARRINI, Juozas KUPCINSKAS, Frode LERANG, Sinead SMITH, Oleksiy GRIDNYEV, Marcis LEJA, Theodore ROKKAS, Ricardo MARCOS-PINTO, Antonio MESTROVIC, Wojciech MARLICZ, Vladimir MILIVOJEVIC, Halis SIMSEK, Lumír KUNOVSKÝ, Veronika PAPP, Perminder PHULL, Marino VENERITO, Lyudmila BOYANOVA, Doron BOLTIN, Yaron NIV, Tamara MATYSIAK-BUDNIK, Michael DOULBERIS, Daniela DOBRU, Vincent LAMY, Lisette CAPELLE, Emilijia Nikolovska TRPCHEVSKA, Leticia MOREIRA, Anna CANO-CATALIA, Pablo PARRA, Francis MEGRAUD, Colm MORAIN, Guillermo ORTEGA, Javier GISBERT and Hp EuReg INVESTIGATORS. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013-2022: Data from the European Registry on H. pylori Management (Hp-EuReg). Antibiotics-Basel. BASEL: MDPI, 2023, vol. 12, No 9, p. 1-18. ISSN 2079-6382. Available from: https://dx.doi.org/10.3390/antibiotics12091427.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013-2022: Data from the European Registry on H. pylori Management (Hp-EuReg)
Authors NYSSEN, Olga, Pietro PRATESI, Miguel SPINOLA, Laimas JONAITIS, Angeles PEREZ-AISA, Dino VAIRA, Ilaria Maria SARACINO, Matteo PAVONI, Giulia FIORINI, Bojan TEPES, Dmitry BORDIN, Irina VOYNOVAN, Angel LANAS, Samuel MARTINEZ-DOMINGUEZ, Enrique ALFARO, Luis BUJANDA, Manuel PABON-CARRASCO, Luis HERNANDEZ, Antonio GASBARRINI, Juozas KUPCINSKAS, Frode LERANG, Sinead SMITH, Oleksiy GRIDNYEV, Marcis LEJA, Theodore ROKKAS, Ricardo MARCOS-PINTO, Antonio MESTROVIC, Wojciech MARLICZ, Vladimir MILIVOJEVIC, Halis SIMSEK, Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Veronika PAPP, Perminder PHULL, Marino VENERITO, Lyudmila BOYANOVA, Doron BOLTIN, Yaron NIV, Tamara MATYSIAK-BUDNIK, Michael DOULBERIS, Daniela DOBRU, Vincent LAMY, Lisette CAPELLE, Emilijia Nikolovska TRPCHEVSKA, Leticia MOREIRA, Anna CANO-CATALIA, Pablo PARRA, Francis MEGRAUD, Colm MORAIN, Guillermo ORTEGA, Javier GISBERT and Hp EuReg INVESTIGATORS.
Edition Antibiotics-Basel, BASEL, MDPI, 2023, 2079-6382.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.800 in 2022
RIV identification code RIV/00216224:14110/23:00132561
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/antibiotics12091427
UT WoS 001074506900001
Keywords in English Helicobacter pylori; clustering; phenotyping; machine learning; treatment; eradication
Tags 14110223, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/2/2024 09:54.
Abstract
The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the "most important" variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013-2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin-clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth-quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin-amoxicillin-metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.
PrintDisplayed: 10/7/2024 20:38